Zobrazeno 1 - 10 of 248 pro vyhledávání: '"Edward L Korn"'
1
Augmenting randomized clinical trial data with historical control data: Precision medicine applications
Autor: Boris Freidlin, Edward L Korn
Publikováno v: J Natl Cancer Inst
As precision medicine becomes more precise, the sizes of the molecularly targeted subpopulations become increasingly smaller. This can make it challenging to conduct randomized clinical trials of the targeted therapies in a timely manner. To help wit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::676faa350ed704c8b2e75235f8b0d8a0
https://doi.org/10.1093/jnci/djac185
Zobrazit plný text záznamu
5
Data from Chromosome Transfer Induced Aneuploidy Results in Complex Dysregulation of the Cellular Transcriptome in Immortalized and Cancer Cells
Autor: Thomas Ried, Michael J. Difilippantonio, J. Carl Barrett, Edward L. Korn, Lisa M. McShane, Jens K. Habermann, Madhvi B. Upender
Chromosomal aneuploidies are observed in essentially all sporadic carcinomas. These aneuploidies result in tumor-specific patterns of genomic imbalances that are acquired early during tumorigenesis, continuously selected for and faithfully maintained
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f50ed185f641da09a0c3c0c91ca627f
https://doi.org/10.1158/0008-5472.c.6493673.v1
Zobrazit plný text záznamu
6
Clinical Benefit Scales and Trial Design: Some Statistical Issues
Autor: Edward L Korn, Carmen J Allegra, Boris Freidlin
Publikováno v: J Natl Cancer Inst
Recently developed clinical-benefit outcome scales by the European Society for Medical Oncology and the American Society of Clinical Oncology allow standardized objective evaluation of outcomes of randomized clinical trials. However, incorporation of
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9bb198f644dd728e6714b3240093f8ec
https://doi.org/10.1093/jnci/djac099
Zobrazit plný text záznamu
8
A Problematic Biomarker Trial Design
Autor: Boris Freidlin, Edward L. Korn
Publikováno v: J Natl Cancer Inst
Efficient biomarker-driven randomized clinical trials are a key tool for implementing precision oncology. A commonly used biomarker phase III design is focused on testing the treatment effect in biomarker-positive and overall study populations. This
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::689146e2a9cb5ce018a3e28c88a002cf
https://doi.org/10.1093/jnci/djab144
Zobrazit plný text záznamu
9
Are restricted mean survival time methods especially useful for noninferiority trials?
Autor: Edward L. Korn, Chen Hu, Boris Freidlin
Publikováno v: Clin Trials
Background: Restricted mean survival time methods compare the areas under the Kaplan–Meier curves up to a time [Formula: see text] for the control and experimental treatments. Extraordinary claims have been made about the benefits (in terms of dram
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69536a93c1bb5d13a52147b21c0253e8
https://doi.org/10.1177/1740774520976576
Zobrazit plný text záznamu
10
Moving Molecular Profiling to Routine Clinical Practice: A Way Forward?
Autor: Carmen J. Allegra, Boris Freidlin, Edward L. Korn
Publikováno v: J Natl Cancer Inst
Molecular profiling of a patient’s tumor to guide targeted treatment selection offers the potential to advance patient care by improving outcomes and minimizing toxicity (by avoiding ineffective treatments). However, current development of molecula
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::81cdfaff662a4b7a078785c941e3870a
https://doi.org/10.1093/jnci/djz240
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje